Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Ascendis Pharma A/S | TransCon hGH/TransCon CNP combination - (COACH) | Achondroplasia | Phase 2 | Data Released | Subcutaneous | Genetic Disorder |
| Ascendis Pharma A/S | TransCon hGH - (InsiGHTS) | Turner Syndrome | Phase 2 | Data Released | Subcutaneous | Genetic Disorder |
| Ascentage Pharma Group International | APG-2449 | Solid tumors | Phase 3 | Enrollment Initiation | oral | Oncology |
| Ascentage Pharma Group International | Olverembatinib | Tyrosine kinase inhibitor (TKI)-resistant/intolerant chronic-phase chronic myeloid leukemia (CML-CP) | Phase 2 | Data Released | Oral | Oncology |
| Ascentage Pharma Group International | Alrizomadlin (APG-115) | Adenoid cystic carcinoma (ACC) | Phase 2 | Ongoing | Oral | Oncology |
| Ascentage Pharma Group International | Olverembatinib - (POLARIS-1) | Acute lymphoblastic leukemia (ALL) | Phase 3 | Data Released | Oral | Oncology |
| Ascentage Pharma Group International | Pelcitoclax (APG-1252) | EGFR-mutant NSCLC, relapsed/refractory non-Hodgkin lymphoma, ovarian cancer, and endometrial carcinoma | Phase 2 | Ongoing | Intravenous | Oncology |
| Ascentage Pharma Group International | Lisaftoclax | Relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) | Phase 2 | Data Released | Oral | Oncology |
